Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

被引：27

作者：

Gatta M.D.M.F.D. ^{[1
,3
]}

Buelga D.S. ^{[1
]}

Navarro A.S. ^{[1
]}

Dominguez-Gil A. ^{[1
,2
]}

García M.J. ^{[1
]}

机构：

[1] Department of Pharmacy and Pharmaceutical Technology, University of Salamanca, Salamanca

[2] Service of Pharmacy, University Hospital of Salamanca, Salamanca

[3] Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, 37007 Salamanca, Avda. Lcdo. Mendez Nieto

来源：

Clinical Pharmacokinetics | 2009年 / 48卷 / 4期

关键词：

Minimum Inhibitory Concentration; Vancomycin; Monte Carlo Simulation; Population Pharmacokinetic Model; Acute Myeloblastic Leukaemia;

D O I：

10.2165/00003088-200948040-00005

中图分类号：

学科分类号：

摘要：

Background: The use of vancomycin against Staphylococcus aureus is currently debated because of the increasing resistance developed by this pathogen. Nevertheless, antibacterial effectiveness is a limited resource that must be protected and restored. Novel dosage strategies based on pharmacokinetic/pharmacodynamic analyses are needed to retain effectiveness that could improve drug exposure in patients infected with such pathogens. Objective: The aim of this study was to assess whether standard or higher vancomycin dosages are required to increase the probability of attaining a target pharmacokinetic/pharmacodynamic index for several staphylococcal strains and thus to estimate the minimum vancomycin daily dose related to a high probability of effective treatment in patients with malignant haematological disease. Methods: Monte Carlo simulation was performed to calculate the cumulative fraction of response (CFR) for different vancomycin daily dosages, using a population pharmacokinetic model previously defined in patients with malignant haematological disease and the minimum inhibitory concentration (MIC) distribution for vancomycin against several staphylococcal species (vancomycin-susceptible S. aureus and vancomycinintermediate S. aureus [VISA], S. epidermidis, S. haemolyticus and coagulase-negative Staphylococcus [CNS] species) obtained from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in order to predict the dose that would achieve the pharmacokinetic/pharmacodynamic index value associated with efficacy (the area under the oncentration-time curve from 0 to 24 hours divided by theMIC [AUC24/MIC≥400]). Results: CFR values showed dependence on the renal function of the patient and the causative pathogen. Only in patients with a creatinine clearance (CLCR) >60mL/min did the standard vancomycin dosage (2000mg/day) induce CFRs >60% for all staphylococci, except the VISA strains. CFRs for S. aureus of 90.6%, 47.3% and 31.2% for CLCR values of <60, 60-120 and 120mL/min, respectively, were obtained, whereas for the VISA strains, the corresponding values were only 14.0%, 0.3% and 0%. The impact of potential pathogens on CFRs is also significant. According to our pharmacokinetic/ pharmacodynamic analysis, in patients with normal renal function (CLCR between 60 and 120mL/min) vancomycin 2000mg/day leads to a risk of not achieving the recommended AUC24/MIC breakpoint of 52.7%, 70.4%, 74.9% and 80.3% for S. aureus, S. haemolyticus, CNS and S. epidermidis, respectively. Application of our results to clinical practice graphically allows us to obtain the recommended dose for any a priori-selected probability of attaining the AUC24/MIC ratio of ≥400 and to evaluate the CFRs for any dosing regimen used in this population group, depending on the patients' renal function. Conclusions: Application of pharmacokinetic/pharmacodynamic analysis based on Monte Carlo simulationoffers an excellent tool for selecting the therapeutic option with the highest probability of clinical success in patients with malignant haematological disease. Thus, for vancomycin-susceptible S. aureus, if a CFR ≥80 is assumed as clinically acceptable, vancomycin doses of 1500, 3000 and 4000 mg/day for a CLCR of >60, 60-120 and <120mL/min, respectively, will be required. © 2009 Adis Data Information BV.

引用

页码：273 / 280

页数：7

共 33 条

[11]

Kuti J.L., Nicolau D.P., Making the most of surveillance studies: Summary of the OPTAMA Program, Diagn Microbiol Infect Dis, 53, 4, pp. 281-287, (2005)

[12]

Moise-Broder P.A., Forrest A., Birmingham M.C., Et al., Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections, Clin Pharmacokinet, 43, 13, pp. 925-942, (2004)

[13]

Fernandez de Gatta M.M., Revilla N., Calvo M.V., Et al., Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients, Intensive Care Med, 33, pp. 279-285, (2007)

[14]

Buelga D.S., Fernandez de Gatta M.M., Herrera E.V., Et al., Population pharma-cokinetic analysis ofvancomycinin patients with hematological malignancies, Antimicrob Agents Chemother, 49, 12, pp. 4934-4941, (2005)

[15]

Kantzanou K., Tassios P.T., Tseleni-Kotsovili A., Et al., Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus, J Antimicrob Chemother, 43, pp. 729-731, (1999)

[16]

The European Committee on Antimicrobial Susceptibility Testing - Eucast

[17]

Mouton J.W., Dudley M.N., Cars O., Et al., Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update, J Antimicrob Chemother, 55, 5, pp. 601-607, (2005)

[18]

Machain L., SimulAr: Montecarlo simulation in Excel

[19]

Cockroft D.W., Gault M.H., Prediction of creatinine clearance from serum creatinine, Nephron, 16, pp. 31-41, (1976)

[20]

Deresinski S., Principles of antibiotic therapy in severe infections: Optimizing the therapeutic approach by use of laboratory and clinical data, Clin Infect Dis, 45, 3 SUPPL., (2007)

← 1 2 3 4 →